Name | Olmesartan |
Synonyms | Olmesartan n-Butyl OlMesartan MedoxoMil Olmesartan Medoxomil Impurity E 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-butyl-4-(2-hydroxy-2-propanyl)-1-{[2'-(2H-tetrazol-5-yl)-4-biphenylyl]methyl}-1H-imidazole-5-carboxylate (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-(2-hydroxypropan-2-yl)-1H-imidazole-5-carboxylate 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER 1H-Imidazole-5-carboxylic acid, 2-butyl-4-(1-hydroxy-1-methylethyl)-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-, (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER |
CAS | 144689-78-1 |
InChI | InChI=1S/C30H32N6O6/c1-5-6-11-24-31-26(30(3,4)39)25(28(37)40-17-23-18(2)41-29(38)42-23)36(24)16-19-12-14-20(15-13-19)21-9-7-8-10-22(21)27-32-34-35-33-27/h7-10,12-15,39H,5-6,11,16-17H2,1-4H3,(H,32,33,34,35) |
Molecular Formula | C30H32N6O6 |
Molar Mass | 572.61 |
Density | 1.36 |
Boling Point | 808.7±75.0 °C(Predicted) |
Flash Point | 442.916 °C |
pKa | 4.15±0.10(Predicted) |
Storage Condition | -20℃ |
Physical and Chemical Properties |
|
white or pale yellow to white powder or crystalline powder. mp180 ~ 182 deg C (decomposition). Practically insoluble in water, insoluble in methanol.
potassium carbonate, dissolved in dimethylacetamide, is added dropwise with stirring at 60 °c, containing 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid (5-methyl -2-oxy -1.3-dioxole -4-yl) methyl Ester and 4-[2-(triphenylmethyltetrazol-5-yl) phenyl] benzyl bromide dimethyl acetamide solution, stirred reaction, after treatment, 4-(1-hydroxy-1-methylethyl)-2-propyl -1-[4-2-(triphenylmethyltetrazole-5-yl) phenyl] methylimidazole-5-carboxylic acid (5-methyl -2-oxy -1,3-= oxocyclopenten-4-yl) methyl ester. This was stirred with 75% aqueous acetic acid at 60 °c and treated to give olmesartan.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.746 ml | 8.732 ml | 17.464 ml |
5 mM | 0.349 ml | 1.746 ml | 3.493 ml |
10 mM | 0.175 ml | 0.873 ml | 1.746 ml |
5 mM | 0.035 ml | 0.175 ml | 0.349 ml |
It was developed by santhereby Pharma( Parsippany,NJ) Co. Ltd. It was approved for marketing in the United States by the U. S. Food and Drug Administration (FDA) in April 2002. An orally effective non-peptide angiotensin II receptor antagonist. Angiotensin converting enzyme II antagonist, used in the treatment of hypertension.